**Appendix Table E83. Results from studies assessing the ability of TEG to predict myocardial infarction in patients with ischemic heart disease**

| **Author,year**  **UID**  **Country**  **Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)**  **[statistical test]** | **Adjusted?**  **[YES/NO/NR]**  **If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bliden, 2006  17291930  USA  NR | clopidogrel  75 mg qd | ADP-induced platelet reactivity | Myocardial infarction | Myocardial infarction | Day 0-30 | HPR n=22 | Myocardial infarction | 3/22 | OR=12.2 (calculated) | 1.2-123.5 | p=0.03  HPR vs NPR  Fisher’s exact test | NR | NR |  |
|  | clopidogrel  75 mg qd | ADP-induced platelet reactivity | Myocardial infarction | Myocardial infarction | Day 0-30 | NPR  N=78 | Myocardial infarction | 1/78 |  |  |  |  |  |  |
|  | clopidogrel  75 mg qd | ADP-induced platelet reactivity | Myocardial infarction | Myocardial infarction | Day 31-365 | HPR n=22 | Myocardial infarction | 1/22 | OR=10.95 (calculate) | 0.4-278.6 | P=0.15  HPR vs NPR  Fisher’s exact test | NR | NR |  |
|  | clopidogrel  75 mg qd | ADP-induced platelet reactivity | Myocardial infarction | Myocardial infarction | Day 31-365 | NPR  N=78 | Myocardial infarction | 0/78 |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Tang, 2012  22490487  China  NR | 100mg aspirin and 75 mg clopidogrel (con) | ADP-induced platelet reactivity | MI | myocardial infarction | 6 months | control group | MI | 0/30=0 | OR=13.16  (calculate) | 0.69-249.48 | <0.05 con vs R+R  ANOVA | NR | NR | from table 4 |
|  | 100mg aspirin and 75 mg clopidogrel (R+R) |  |  |  | 6 months | resistance plus routine |  | 5/30=17% |  |  | <0.05 R+R vs R+L  ANOVA |  |  |  |
|  | 200mg aspirin and150 mg clopidogrel (R+L) |  |  |  | 6 months | resistance plus loading dose |  | 2/30=6% |  |  | <0.05 con vs R+L  ANOVA |  |  |  |
|  | 100mg aspirin and 75 mg clopidogrel (con) | ADP-induced platelet reactivity | MI | myocardial infarction | 12 months | control group | MI | 0/30=0 | OR=16. 18(calculated) | 0.87-301.62 | <0.05 con vs R+R  ANOVA | NR | NR | from table 5 |
|  | 100mg aspirin and 75 mg clopidogrel (R+R) |  |  |  | 12months | resistance plus routine |  | 6/30=20% |  |  | <0.05 R+R vs R+L  ANOVA |  |  |  |
|  | 200mg aspirin and150 mg clopidogrel (R+L) |  |  |  | 12 months | resistance plus loading dose |  | 3/30=6% |  |  | <0.05 con vs R+L  ANOVA |  |  |  |